Screener / SEC EDGAR /CIK 0000882796 /10-K filed Feb 26, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Biocryst Pharmaceuticals Inc BCRX

Compare with peers Embed
Earnings releases

Latest results release: Nov 4, 2026

8-K item 2.02, exhibit 99

What BCRX's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

Non-GAAP net income, excluding stock-based compensation expense, transaction-related costs, and loss on extinguishment of debt was $35.6 million, or $0.17 per share, for the third quarter of 2025, compared to $3.2 million, or $0.02 per share, for the third quarter of 2024. release Nov 3, 2025

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 4, 2026 · EX-99.1

BioCryst Reports Third Quarter 2026 Financial Results

Open on SEC

EXHIBIT 99.1 BioCryst Reports Third Quarter 2026 Financial Results — Total net revenue of $180.3 million and ORLADEYOnet revenue of $174.8 million —

— Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million —

— Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million —

— Received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older —

RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended September 30, 2026, and provided a business update.

"In the third quarter, we delivered continued growth of ORLADEYO and strong profitability while broadening the foundation for our long-term success," said Charlie Gayer, President and Chief Executive Officer of BioCryst. “We successfully launched ORLADEYO pellets in pediatric patients, received FDA approval for their use in adolescents and adults in October, and implemented our specialty pharmacy transition to CareMed, all of which will make ORLADEYO accessible for more patients. Looking to our pipeline, BCX17725 remains on track for the early clinical data by the end of this year, and we look forward to navenibart pivotal results in the third quarter of 2027. This progress across our business increases our confidence in our ability to drive sustainable growth and lasting value for patients and shareholders."

Total revenues were $180.3 million (+13% y-o-y; +24% y-o-y on a comparable basis excluding European revenue). Revenue growth in the quarter benefited from the transition to CareMed as the company's sole-source specialty pharmacy partner for shipments to patients. As part of its distribution model, CareMed built an initial inventory of ORLADEYO to support patient demand and efficient dispensing, consistent with customary specialty pharmacy practices. The company expects that inventory level to remain relatively stable over time. ORLADEYO revenue, excluding European revenue, grew year-over-year when removing the effect of the initial inventory build.

Research and development expenses, excluding stock-based compensation expense, were $52.4 million for the third quarter of 2026. Research and development expenses for the quarter include one-time impairment charges associated with the closure of the Birmingham site and employee termination costs. Total restructuring costs in research and development included cash costs of $6.3 million and non-cash costs of $9.3 million.

Sales and marketing expenses, excluding stock-based compensation expense, were $37.7 million (-15% y-o-y) on a GAAP basis and $36.0 million (+4% y-o-y) on a non-GAAP basis. Fees related to the specialty pharmacy transition contributed to the increase. General and administrative expenses, excluding stock-based compensation expense, were $21.0 million (-22% y-o-y) on a GAAP basis and $19.1 million (-8% y-o-y) on a non-GAAP basis.

The company recorded an operating profit of $53.3 million for the third quarter of 2026 compared to $29.6 million for the third quarter of 2025.

The company recorded net income of $37.9 million for the third quarter of 2026 compared to $12.9 million for third quarter of 2025.

During Q3 2026, the company generated positive cash flow. As a result, cash, cash equivalents, restricted cash and investments totaled $376.4 million on September 30, 2026.

The accompanying tables provide GAAP and non-GAAP financial information for the three and nine months ended September 30, 2026. Non-GAAP measures include adjustments, as applicable, for the sale of the European ORLADEYO business on October 1, 2025 (including transaction-related costs), stock-based compensation, expenses incurred in connection with the acquisition of Astria on January 23, 2026, employee termination and impairment charges related to the Birmingham site closure, and workforce reduction expenses. Management believes that the presentation of these non-GAAP figures provides greater transparency into the financial results of core, ongoing operations and improves comparability across reporting periods by excluding items that are non-recurring or other items that may vary significantly from period to period.

The company maintained its outlook for full year 2026 global net ORLADEYO revenue of $625 million to $645 million and increased its full year 2026 total revenue outlook, including revenue from RAPIVAB (peramivir injection) and the licensing of navenibart European rights, to $715 million to $730 million. The increase was primarily driven by higher revenues from the licensing of navenibart rights, as well as higher RAPIVAB orders from international partners.

The company improved its outlook for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to $415 million to $425 million. The decrease was primarily driven by continued progress on the Birmingham site closure.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET today to discuss the financial results and provide a corporate update. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

The information furnished in this release and the accompanying tables includes non-GAAP financial measures that differ from measures calculated in accordance with generally accepted accounting principles in the United States of America (“GAAP”), including financial measures labeled as “non-GAAP.” As noted under “Third Quarter 2026 Financial Results” above, we believe providing these non- GAAP measures, which show our results with certain items adjusted, is valuable and useful since they can provide greater transparency into the financial results of core, ongoing operations and improve comparability across reporting periods. These non-GAAP measures also correspond with the way we expect investors and financial analysts to compare our results. Our non-GAAP measures should be considered only as supplements to, and not as substitutes for or in isolation from, our other measures of financial information prepared in accordance with GAAP. A reconciliation between each non-GAAP financial measure and its respective closest equivalent GAAP financial measure is provided in the tables below.

We also provide our non-GAAP operating expense outlook for full year 2026, which refers to our expected GAAP operating expense, excluding stock-based compensation, restructuring and transaction-related costs. We have not provided a reconciliation against the comparable forward-looking GAAP measure because we are unable to predict with reasonable certainty the full amount of stock-based compensation expense or restructuring or transaction-related costs for the full year 2026 without unreasonable effort. Stock-based compensation expense is uncertain and depends on various factors, including our future hiring and retention needs, as well as the future fair market value of our common stock, which is difficult to predict and subject to change. In addition, we are unable to predict with reasonable certainty the full amount of restructuring and transaction-related costs as the related costs are dependent on various factors that have not yet or have only recently occurred. The actual amount of stock- based compensation, restructuring and transaction-related costs for the full year 2026 could have a material impact on GAAP reported results for the guidance period.

This press release contains forward-looking statements, including statements regarding future results, performance or achievements, such as expected full year 2026 revenue and operating expenses, expectations regarding pipeline development, including with respect to the timing of data and plans to report such data, accessibility of ORLADEYO for patients, expectations regarding BioCryst’s future growth and value creation, expectations related to the closure of BioCryst’s Birmingham research facility and wind-down of internal discovery programs, including statements about the expected timing, cost and anticipated related future cost savings, and expectations related to the CareMed transition, including future inventory levels and purchasing patterns. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s ability to successfully progress its pipeline development plans as described herein, including meeting the expected timelines; BioCryst’s ability to successfully transition to CareMed and to continue to successfully commercialize ORLADEYO, including the successful launch of the ORLADEYO oral pellet formulation; BioCryst’s ability to successfully execute its plan to close the Birmingham research facility and wind-down its internal discovery programs, including the timing and costs of such actions and its ability to realize the anticipated cost savings; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; BioCryst may not advance human clinical trials with product candidates as expected; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations, including that our partners may fail to reach performance milestones or achieve certain royalty thresholds under our license agreements; statements and projections regarding financial guidance and goals and the attainment of such goals may differ from actual results based on market factors and BioCryst’s ability to execute its operational and budget plans; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management’s expected ranges. This list is not exclusive. To see a more comprehensive list of risks, please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

Reve… and expe… asso… with our Euro… ORLA… busi… which was sold to Neop… Gent… S.p.… on Octo… 1, 2025:

Reve… and expe… asso… with our Euro… ORLA… busi… which was sold to Neop… Gent… S.p.… on Octo… 1, 2025:

ORLA… $ 38,6… reve… Cost of prod… $ 2,465 sales - ORLA… Rese… and deve… $ 1,539 (exc… stoc… comp… Sales and mark… $ 30,4… (exc… stoc… comp… Gene… and admi… $ 8,089 (exc… stoc… comp… Tran… $ 9,933 costs Stoc… $ 61,2… comp… Loss on exti… $ 6,911 of debt Reim… of tran… costs asso… with the sale of $ (2,1… ) our Euro… ORLA… busi… to Neop… Gent… S.p.… ²Cer… tran… costs were reim… and reco… in other inco…

Full text with the tables
                                                                    EXHIBIT 99.1
             BioCryst Reports Third Quarter 2026 Financial Results              
— Total net revenue of $180.3 million and ORLADEYOnet revenue of $174.8 million
—

— Operating profit of $53.3 million and Non-GAAP operating profit of $86.5
million —

— Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million
and increased total revenue guidance to $715 million to $730 million —

— Improved Non-GAAP operating expense guidance to $415 to $425 million —

— Received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12
and older —

RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst
Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the
quarter ended September 30, 2026, and provided a business update.

"In the third quarter, we delivered continued growth of ORLADEYO and strong
profitability while broadening the foundation for our long-term success," said
Charlie Gayer, President and Chief Executive Officer of BioCryst. “We
successfully launched ORLADEYO pellets in pediatric patients, received FDA
approval for their use in adolescents and adults in October, and implemented our
specialty pharmacy transition to CareMed, all of which will make ORLADEYO
accessible for more patients. Looking to our pipeline, BCX17725 remains on track
for the early clinical data by the end of this year, and we look forward to
navenibart pivotal results in the third quarter of 2027. This progress across
our business increases our confidence in our ability to drive sustainable growth
and lasting value for patients and shareholders."

Business & Corporate Updates

Third Quarter 2026 Financial Results

Total revenues were $180.3 million (+13% y-o-y; +24% y-o-y on a comparable basis
excluding European revenue). Revenue growth in the quarter benefited from the
transition to CareMed as the company's sole-source specialty pharmacy partner
for shipments to patients. As part of its distribution model, CareMed built an
initial inventory of ORLADEYO to support patient demand and efficient
dispensing, consistent with customary specialty pharmacy practices. The company
expects that inventory level to remain relatively stable over time. ORLADEYO
revenue, excluding European revenue, grew year-over-year when removing the
effect of the initial inventory build.

Research and development expenses, excluding stock-based compensation expense,
were $52.4 million for the third quarter of 2026. Research and development
expenses for the quarter include one-time impairment charges associated with the
closure of the Birmingham site and employee termination costs. Total
restructuring costs in research and development included cash costs of $6.3
million and non-cash costs of $9.3 million.

Sales and marketing expenses, excluding stock-based compensation expense, were
$37.7 million (-15% y-o-y) on a GAAP basis and $36.0 million (+4% y-o-y) on a
non-GAAP basis. Fees related to the specialty pharmacy transition contributed to
the increase. General and administrative expenses, excluding stock-based
compensation expense, were $21.0 million (-22% y-o-y) on a GAAP basis and $19.1
million (-8% y-o-y) on a non-GAAP basis.

The company recorded an operating profit of $53.3 million for the third quarter
of 2026 compared to $29.6 million for the third quarter of 2025.

The company recorded net income of $37.9 million for the third quarter of 2026
compared to $12.9 million for third quarter of 2025.

During Q3 2026, the company generated positive cash flow. As a result, cash,
cash equivalents, restricted cash and investments totaled $376.4 million on
September 30, 2026.

The accompanying tables provide GAAP and non-GAAP financial information for the
three and nine months ended September 30, 2026. Non-GAAP measures include
adjustments, as applicable, for the sale of the European ORLADEYO business on
October 1, 2025 (including transaction-related costs), stock-based compensation,
expenses incurred in connection with the acquisition of Astria on January 23,
2026, employee termination and impairment charges related to the Birmingham site
closure, and workforce reduction expenses. Management believes that the
presentation of these non-GAAP figures provides greater transparency into the
financial results of core, ongoing operations and improves comparability across
reporting periods by excluding items that are non-recurring or other items that
may vary significantly from period to period.

Financial Outlook for 2026

The company maintained its outlook for full year 2026 global net ORLADEYO
revenue of $625 million to $645 million and increased its full year 2026 total
revenue outlook, including revenue from RAPIVAB (peramivir injection) and the
licensing of navenibart European rights, to $715 million to $730 million. The
increase was primarily driven by higher revenues from the licensing of
navenibart rights, as well as higher RAPIVAB orders from international partners.

The company improved its outlook for full year 2026 non-GAAP operating expenses,
excluding stock-based compensation, restructuring, and transaction-related
costs, to $415 million to $425 million. The decrease was primarily driven by
continued progress on the Birmingham site closure.
                                                                                
  Item                     As of November 4, 2026     As of August 5, 2026      
 ────────────────────────────────────────────────────────────────────────────── 
  ORLADEYO revenue         Unchanged                  $625 million to $645      
                                                      million                   
  Total revenue            $715 million to $730       $690 million to $715      
                           million                    million                   
  Non-GAAP operating       $415 million to $425       $420 million to $440      
  expense                  million                    million                   
                                                                                
Conference Call and Webcast

BioCryst management will host a conference call and webcast at 8:30 a.m. ET
today to discuss the financial results and provide a corporate update. A live
webcast and replay of the call will be available online in the investors section
of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst is a global biotechnology company focused on developing and
commercializing medicines for hereditary angioedema (“HAE”) and other rare
diseases, driven by its deep commitment to improving the lives of people living
with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the
first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline
of potential first-in-class or best-in-class therapeutics for rare diseases. For
more information, please visit www.biocryst.com or follow us on LinkedIn.

Non-GAAP Financial Measures

The information furnished in this release and the accompanying tables includes
non-GAAP financial measures that differ from measures calculated in accordance
with generally accepted accounting principles in the United States of America
(“GAAP”), including financial measures labeled as “non-GAAP.” As noted under
“Third Quarter 2026 Financial Results” above, we believe providing these non-
GAAP measures, which show our results with certain items adjusted, is valuable
and useful since they can provide greater transparency into the financial
results of core, ongoing operations and improve comparability across reporting
periods. These non-GAAP measures also correspond with the way we expect
investors and financial analysts to compare our results. Our non-GAAP measures
should be considered only as supplements to, and not as substitutes for or in
isolation from, our other measures of financial information prepared in
accordance with GAAP. A reconciliation between each non-GAAP financial measure
and its respective closest equivalent GAAP financial measure is provided in the
tables below.

We also provide our non-GAAP operating expense outlook for full year 2026, which
refers to our expected GAAP operating expense, excluding stock-based
compensation, restructuring and transaction-related costs. We have not provided
a reconciliation against the comparable forward-looking GAAP measure because we
are unable to predict with reasonable certainty the full amount of stock-based
compensation expense or restructuring or transaction-related costs for the full
year 2026 without unreasonable effort. Stock-based compensation expense is
uncertain and depends on various factors, including our future hiring and
retention needs, as well as the future fair market value of our common stock,
which is difficult to predict and subject to change. In addition, we are unable
to predict with reasonable certainty the full amount of restructuring and
transaction-related costs as the related costs are dependent on various factors
that have not yet or have only recently occurred. The actual amount of stock-
based compensation, restructuring and transaction-related costs for the full
year 2026 could have a material impact on GAAP reported results for the guidance
period.

Forward-Looking Statements

This press release contains forward-looking statements, including statements
regarding future results, performance or achievements, such as expected full
year 2026 revenue and operating expenses, expectations regarding pipeline
development, including with respect to the timing of data and plans to report
such data, accessibility of ORLADEYO for patients, expectations regarding
BioCryst’s future growth and value creation, expectations related to the closure
of BioCryst’s Birmingham research facility and wind-down of internal discovery
programs, including statements about the expected timing, cost and anticipated
related future cost savings, and expectations related to the CareMed transition,
including future inventory levels and purchasing patterns. These statements
involve known and unknown risks, uncertainties and other factors which may cause
BioCryst’s actual results, performance, or achievements to be materially
different from any future results, performance, or achievements expressed or
implied by the forward-looking statements. These statements reflect our current
views with respect to future events and are based on assumptions and are subject
to risks and uncertainties. Given these uncertainties, you should not place
undue reliance on these forward-looking statements. Some of the factors that
could affect the forward-looking statements contained herein include: BioCryst’s
ability to successfully progress its pipeline development plans as described
herein, including meeting the expected timelines; BioCryst’s ability to
successfully transition to CareMed and to continue to successfully commercialize
ORLADEYO, including the successful launch of the ORLADEYO oral pellet
formulation; BioCryst’s ability to successfully execute its plan to close the
Birmingham research facility and wind-down its internal discovery programs,
including the timing and costs of such actions and its ability to realize the
anticipated cost savings; ongoing and future preclinical and clinical
development of product candidates may take longer than expected and may not have
positive results; the outcome of preclinical testing and early clinical trials
may not be predictive of the success of later clinical trials, and interim
results of a clinical trial do not necessarily predict final results; BioCryst
may not advance human clinical trials with product candidates as expected; the
FDA or other applicable regulatory agency may require additional studies beyond
the studies planned for products and product candidates, may not provide
regulatory clearances which may result in delay of planned clinical trials, may
not review regulatory filings on our expected timeline, may impose certain
restrictions, warnings, or other requirements on products and product
candidates, may impose a clinical hold with respect to product candidates, or
may withhold, delay or withdraw market approval for products and product
candidates; the results of BioCryst’s partnerships with third parties may not
meet BioCryst’s current expectations, including that our partners may fail to
reach performance milestones or achieve certain royalty thresholds under our
license agreements; statements and projections regarding financial guidance and
goals and the attainment of such goals may differ from actual results based on
market factors and BioCryst’s ability to execute its operational and budget
plans; and actual financial results may not be consistent with expectations,
including that revenue, operating expenses and cash usage may not be within
management’s expected ranges. This list is not exclusive. To see a more
comprehensive list of risks, please refer to the documents BioCryst files
periodically with the Securities and Exchange Commission, specifically
BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K, which identify important factors that
could cause actual results to differ materially from those contained in
BioCryst’s projections and forward-looking statements.

BCRXW

Contact:

Investors:
[email protected]

Media:
[email protected]
                                                                                
  BIOC…                                                                         
  PHAR…                                                                         
  INC.                                                                          
  CONS…                                                                         
  FINA…                                                                         
  SUMM…                                                                         
  (In                                                                           
  thou…                                                                         
  exce…                                                                         
  per                                                                           
  shar…                                                                         
  Stat…    Three                                Nine                            
  of       Months                               Months                          
  Oper…    Ended                                Ended                           
  (Una…    Septe…                               Septe…                          
  Reve…    30,       2026              2025     30,      2026          2025     
 ────────────────────────────────────────────────────────────────────────────── 
  ORLA…    $       174,8…     $       159,…     $       481,…     $  450,1…     
  Lice…                                                                         
  and               5,459               318             73,5…        18,125     
  other                                                                         
  reve…                                                                         
  Total            180,2…             159,…             554,…        468,2…     
  reve…                                                                         
  Expe…                                                                         
  Cost                                                                          
  of                1,574             2,187             10,7…         9,553     
  prod…                                                                         
  sales                                                                         
  Acqu…                                                                         
  in-p…                                                                         
  rese…                 —                 —             697,…             —     
  and                                                                           
  deve…                                                                         
  Rese…                                                                         
  and              58,213             44,6…             170,…        125,2…     
  deve…                                                                         
  Sell…                                                                         
  gene…            67,175             83,0…             225,…        252,8…     
  and                                                                           
  admi…                                                                         
  Total                                                                         
  oper…            126,9…             129,…             1,10…        387,6…     
  expe…                                                                         
  Inco…                                                                         
  (los…            53,330             29,5…             (549…  )     80,604     
  from                                                                          
  oper…                                                                         
  Other                                                                         
  inco…                                                                         
  (exp…                                                                         
  Inte…             3,073             2,238             7,763         7,778     
  inco…                                                                         
  Inte…            (21,1…  )          (19,…  )          (62,…  )     (64,7…  )  
  expe…                                                                         
  Fore…                                                                         
  curr…                                                                         
  gains                22                35              (176  )        (27  )  
  (los…                                                                         
  net                                                                           
  Loss                                                                          
  on                                                                            
  exti…                 —             (2,7…  )              —        (6,911  )  
  of                                                                            
  debt                                                                          
  Other                                                                         
  inco…             3,345             2,667             2,143         2,667     
  net                                                                           
  Total                                                                         
  other            (14,7…  )          (17,…  )          (52,…  )     (61,2…  )  
  expe…                                                                         
  net                                                                           
  Inco…                                                                         
  (los…                                                                         
  befo…            38,585             12,1…             (602…  )     19,374     
  inco…                                                                         
  taxes                                                                         
  Inco…                                                                         
  tax                 669              (769  )          2,752         1,358     
  expe…                                                                         
  (ben…                                                                         
  Net                                                                           
  inco…    $       37,916     $       12,8…     $       (605…  )  $  18,016     
  (los…                                                                         
  Net                                                                           
  inco…                                                                         
  (los…                                                                         
  per      $         0.15     $        0.06     $       (2.41  )  $    0.09     
  comm…                                                                         
  shar…                                                                         
  basic                                                                         
  Weig…                                                                         
  aver…                                                                         
  shar…                                                                         
  of               255,6…             210,…             250,…        209,5…     
  comm…                                                                         
  stock                                                                         
  outs…                                                                         
  basic                                                                         
  Net                                                                           
  inco…                                                                         
  (los…                                                                         
  per      $         0.14     $        0.06     $       (2.41  )  $    0.08     
  comm…                                                                         
  shar…                                                                         
  dilu…                                                                         
  Weig…                                                                         
  aver…                                                                         
  shar…                                                                         
  of               267,6…             219,…             250,…        218,3…     
  comm…                                                                         
  stock                                                                         
  outs…                                                                         
  dilu…                                                                         
  Roya…                                                                         
  Fina…                                                                         
  Obli…                                                                         
  (in                                                                           
  thou…                                                                         
           Three                                Nine                            
           Months                               Months                          
           Ended                                Ended                           
           Septe…                               Septe…                          
           30,                                  30,                             
                     2026              2025              2026          2025     
  Non-…                                                                         
  Inte…                                                                         
  Expe…                                                                         
  on       $       12,339     $       12,9…     $       38,6…     $  39,839     
  Roya…                                                                         
  Fina…                                                                         
  Obli…                                                                         
  Total                                                                         
  Cash                                                                          
  Paid                                                                          
  on       $       33,745     $       30,7…     $       74,1…     $  71,646     
  Roya…                                                                         
  Fina…                                                                         
  Obli…                                                                         
  Bala…                                                                         
  Sheet                                                                         
  Data                                                                          
  (in                                                                           
  thou…                                                                         
           Septe…             Decem…                                            
           30,                31,                                               
           2026               2025                                              
           -unau…             Note 1                                            
  Cash,                                                                         
  cash                                                                          
  equi…    $       374,9…     $       335,…                                     
  and                                                                           
  inve…                                                                         
  Rest…             1,451             1,601                                     
  cash                                                                          
  Rece…            121,7…             106,…                                     
  Total            591,0…             514,…                                     
  asse…                                                                         
  Secu…                                                                         
  term             395,6…                 -                                     
  loan                                                                          
  Roya…                                                                         
  fina…            421,6…             465,…                                     
  obli…                                                                         
  Accu…            (2,11…  )          (1,5…  )                                  
  defi…                                                                         
  Stoc…            (397,…  )          (119…  )                                  
  defi…                                                                         
  Shar…                                                                         
  of                                                                            
  comm…            256,1…             213,…                                     
  stock                                                                         
  outs…                                                                         
  Note                                                                          
  1:                                                                            
  Deri…                                                                         
  from                                                                          
  audi…                                                                         
  fina…                                                                         
  stat…                                                                         
  Reco…                                                                         
  of                                                                            
  Non-…                                                                         
  Inco…                                                                         
  From                                                                          
  Oper…                                                                         
  (in                                                                           
  thou…                                                                         
           Three                                                                
           Months                                                               
           Ended                                                                
           Septe…                                                               
           30,                                                                  
           2026                                                                 
           U.S.               Non-G…            Non-G…                          
           GAAP               Adjus…                                            
  Reve…                                                                         
  ORLA…            174,8…                 -             174,…                   
  Lice…                                                                         
  and               5,459                 -             5,459                   
  other                                                                         
  reve…                                                                         
  Total            180,2…                 -             180,…                   
  reve…                                                                         
  Expe…                                                                         
  Cost                                                                          
  of                                                                            
  prod…             1,558                 -             1,558                   
  sales                                                                         
  -                                                                             
  ORLA…                                                                         
  Cost                                                                          
  of                                                                            
  prod…                16                 -                16                   
  sales                                                                         
  -                                                                             
  pera…                                                                         
  Rese…                                                                         
  and                                                                           
  deve…            52,448             15,3…             37,0…                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Sales                                                                         
  and                                                                           
  mark…            37,726             1,703             36,0…                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Gene…                                                                         
  and                                                                           
  admi…            20,970             1,917             19,0…                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Stoc…            14,244             14,2…                 -                   
  comp…                                                                         
  Total                                                                         
  oper…            126,9…             33,2…             93,7…                   
  expe…                                                                         
  Inco…                                                                         
  (los…            53,330             (33,…  )          86,5…                   
  from                                                                          
  oper…                                                                         
  Other                                                                         
  expe…            14,745                 -             14,7…                   
  net                                                                           
  Inco…                                                                         
  tax                 669                 -               669                   
  expe…                                                                         
  (ben…                                                                         
  Net                                                                           
  inco…    $       37,916     $       (33,…  )  $       71,1…                   
  (los…                                                                         
  1Ref…                                                                         
  the                                                                           
  foll…                                                                         
  non-…                                                                         
  adju…                                                                         
  for                                                                           
  the                                                                           
  three                                                                         
  mont…                                                                         
  ended                                                                         
  Sept…                                                                         
  30,                                                                           
  2026:                                                                         
                                                                                
  Expe…                                                                         
  incu…                                                                         
  in                                                                            
  conn…                                                                         
  with                                                                          
  the                                                                           
  Birm…                                                                         
  Clos…                                                                         
  Plan:                                                                         
  Expe…                                                                         
  asso…                                                                         
  with                                          $       6,061                   
  seve…                                                                         
  agre…                                                                         
  Long…                                                                         
  asset                                         $       9,538                   
  impa…                                                                         
  Work…                                         $       3,374                   
  Redu…                                                                         
  Stoc…                                         $       14,2…                   
  comp…                                                                         
           Three                                                                
           Months                                                               
           Ended                                                                
           Septe…                                                               
           30,                                                                  
           2025                                                                 
           U.S.               Non-G…            Non-G…                          
           GAAP               Adjus…                                            
  Reve…                                                                         
  ORLA…            159,0…             13,8…             145,…                   
  Lice…                                                                         
  and                 318                 -               318                   
  other                                                                         
  reve…                                                                         
  Total            159,3…             13,8…             145,…                   
  reve…                                                                         
  Expe…                                                                         
  Cost                                                                          
  of                                                                            
  prod…             2,182               720             1,462                   
  sales                                                                         
  -                                                                             
  ORLA…                                                                         
  Cost                                                                          
  of                                                                            
  prod…                 5                 -                 5                   
  sales                                                                         
  -                                                                             
  pera…                                                                         
  Rese…                                                                         
  and                                                                           
  deve…            38,084                96             37,9…                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Sales                                                                         
  and                                                                           
  mark…            44,114             9,455             34,6…                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Gene…                                                                         
  and                                                                           
  admi…            26,818             6,160             20,6…                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Stoc…            18,601             18,6…                 -                   
  comp…                                                                         
  Total                                                                         
  oper…            129,8…             35,0…             94,7…                   
  expe…                                                                         
  Inco…                                                                         
  from             29,591             (21,…  )          50,8…                   
  oper…                                                                         
  Other                                                                         
  expe…            17,461               623             16,8…                   
  net                                                                           
  Inco…                                                                         
  tax                (769  )              -              (769  )                
  bene…                                                                         
  Net                                                                           
  inco…    $       12,899     $       (21,…  )  $       34,7…                   
  (los…                                                                         
  1Ref…                                                                         
  the                                                                           
  foll…                                                                         
  non-…                                                                         
  adju…                                                                         
  for                                                                           
  the                                                                           
  three                                                                         
  mont…                                                                         
  ended                                                                         
  Sept…                                                                         
  30,                                                                           
  2025:                                                                         
                                                                                
  Reve…                                                                         
  and                                                                           
  expe…                                                                         
  asso…                                                                         
  with                                                                          
  our                                                                           
  Euro…                                                                         
  ORLA…                                                                         
  busi…                                                                         
  which                                                                         
  was                                                                           
  sold                                                                          
  to                                                                            
  Neop…                                                                         
  Gent…                                                                         
  S.p.…                                                                         
  on                                                                            
  Octo…                                                                         
  1,                                                                            
  2025:                                                                         
                                                                                
  ORLA…                                         $       13,8…                   
  reve…                                                                         
  Cost                                                                          
  of                                                                            
  prod…                                         $         720                   
  sales                                                                         
  -                                                                             
  ORLA…                                                                         
  Rese…                                                                         
  and                                                                           
  deve…                                         $          96                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Sales                                                                         
  and                                                                           
  mark…                                         $       9,137                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Gene…                                                                         
  and                                                                           
  admi…                                         $       2,983                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Tran…                                         $       3,495                   
  costs                                                                         
  Stoc…                                         $       18,6…                   
  comp…                                                                         
  Loss                                                                          
  on                                                                            
  exti…                                         $       2,740                   
  of                                                                            
  debt                                                                          
  Reim…                                                                         
  of                                                                            
  tran…                                                                         
  costs                                                                         
  asso…                                                                         
  with                                                                          
  the                                                                           
  sale                                                                          
  of                                            $       (2,1…  )                
  our                                                                           
  Euro…                                                                         
  ORLA…                                                                         
  busi…                                                                         
  to                                                                            
  Neop…                                                                         
  Gent…                                                                         
  S.p.…                                                                         
  ²Cer…                                                                         
  tran…                                                                         
  costs                                                                         
  were                                                                          
  reim…                                                                         
  and                                                                           
  reco…                                                                         
  in                                                                            
  other                                                                         
  inco…                                                                         
           Nine                                                                 
           Months                                                               
           Ended                                                                
           Septe…                                                               
           30,                                                                  
           2026                                                                 
           U.S.               Non-G…            Non-G…                          
           GAAP               Adjus…                                            
  Reve…                                                                         
  ORLA…            481,3…                 -             481,…                   
  Lice…                                                                         
  and              73,573                 -             73,5…                   
  other                                                                         
  reve…                                                                         
  Total            554,9…                 -             554,…                   
  reve…                                                                         
  Expe…                                                                         
  Cost                                                                          
  of                                                                            
  prod…             7,991                 -             7,991                   
  sales                                                                         
  -                                                                             
  ORLA…                                                                         
  Cost                                                                          
  of                                                                            
  prod…             2,800                 -             2,800                   
  sales                                                                         
  -                                                                             
  pera…                                                                         
  Acqu…                                                                         
  in-p…                                                                         
  rese…            697,7…             697,…                 -                   
  and                                                                           
  deve…                                                                         
  Rese…                                                                         
  and                                                                           
  deve…            152,4…             30,8…             121,…                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Sales                                                                         
  and                                                                           
  mark…            114,6…             7,185             107,…                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Gene…                                                                         
  and                                                                           
  admi…            84,173             23,0…             61,1…                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Stoc…            44,963             44,9…                 -                   
  comp…                                                                         
  Total                                                                         
  oper…            1,104…             803,…             301,…                   
  expe…                                                                         
  (Los…                                                                         
  inco…    $       (549,…  )  $       (803…  )  $       253,…                   
  from                                                                          
  oper…                                                                         
  Other                                                                         
  expe…            52,946                 -             52,9…                   
  net                                                                           
  Inco…                                                                         
  tax               2,752                 -             2,752                   
  expe…                                                                         
  Net                                                                           
  inco…    $       (605,…  )  $       (803…  )  $       198,…                   
  (los…                                                                         
  1Ref…                                                                         
  the                                                                           
  foll…                                                                         
  non-…                                                                         
  adju…                                                                         
  for                                                                           
  the                                                                           
  nine                                                                          
  mont…                                                                         
  ended                                                                         
  Sept…                                                                         
  30,                                                                           
  2026:                                                                         
                                                                                
  Expe…                                                                         
  incu…                                                                         
  in                                                                            
  conn…                                                                         
  with                                                                          
  the                                                                           
  acqu…                                                                         
  of                                                                            
  Astr…                                                                         
  Ther…                                                                         
  Inc.                                                                          
  on                                                                            
  Janu…                                                                         
  23,                                                                           
  2026:                                                                         
                                                                                
  Acqu…                                                                         
  in-p…                                                                         
  rese…                                                                         
  and                                           $       697,…                   
  deve…                                                                         
  rela…                                                                         
  to                                                                            
  nave…                                                                         
  Asse…                                                                         
  work…                                         $         600                   
  amor…                                                                         
  Expe…                                                                         
  asso…                                                                         
  with                                                                          
  seve…                                         $       12,3…                   
  and                                                                           
  rete…                                                                         
  award                                                                         
  agre…                                                                         
  Port…                                                                         
  of                                                                            
  stock                                                                         
  opti…                                                                         
  payo…                                         $       29,1…                   
  attr…                                                                         
  to                                                                            
  post…                                                                         
  serv…                                                                         
  Expe…                                                                         
  incu…                                                                         
  in                                                                            
  conn…                                                                         
  with                                                                          
  the                                                                           
  Birm…                                                                         
  Clos…                                                                         
  Plan:                                                                         
  Expe…                                                                         
  asso…                                                                         
  with                                          $       6,061                   
  seve…                                                                         
  agre…                                                                         
  Long…                                                                         
  asset                                         $       9,538                   
  impa…                                                                         
  Work…                                         $       3,374                   
  Redu…                                                                         
  Stoc…                                         $       44,9…                   
  comp…                                                                         
           Nine                                                                 
           Months                                                               
           Ended                                                                
           Septe…                                                               
           30,                                                                  
           2025                                                                 
           U.S.               Non-G…            Non-G…                          
           GAAP               Adjus…                                            
  Reve…                                                                         
  ORLA…            450,1…             38,6…             411,…                   
  Lice…                                                                         
  and              18,125                 -             18,1…                   
  other                                                                         
  reve…                                                                         
  Total            468,2…             38,6…             429,…                   
  reve…                                                                         
  Expe…                                                                         
  Cost                                                                          
  of                                                                            
  prod…             6,564             2,465             4,099                   
  sales                                                                         
  -                                                                             
  ORLA…                                                                         
  Cost                                                                          
  of                                                                            
  prod…             2,989                 -             2,989                   
  sales                                                                         
  -                                                                             
  pera…                                                                         
  Rese…                                                                         
  and                                                                           
  deve…            100,8…             1,539             99,3…                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Sales                                                                         
  and                                                                           
  mark…            137,3…             30,8…             106,…                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Gene…                                                                         
  and                                                                           
  admi…            78,594             17,7…             60,8…                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Stoc…            61,273             61,2…                 -                   
  comp…                                                                         
  Total                                                                         
  oper…            387,6…             113,…             273,…                   
  expe…                                                                         
  Inco…                                                                         
  from             80,604             (75,…  )          155,…                   
  oper…                                                                         
  Other                                                                         
  expe…            61,230             4,794             56,4…                   
  net                                                                           
  Inco…                                                                         
  tax               1,358                 -             1,358                   
  expe…                                                                         
  Net                                                                           
  inco…    $       18,016     $       (79,…  )  $       97,9…                   
  (los…                                                                         
  1Ref…                                                                         
  the                                                                           
  foll…                                                                         
  non-…                                                                         
  adju…                                                                         
  for                                                                           
  the                                                                           
  nine                                                                          
  mont…                                                                         
  ended                                                                         
  Sept…                                                                         
  30,                                                                           
  2025:                                                                         
                                                                                
  Reve…                                                                         
  and                                                                           
  expe…                                                                         
  asso…                                                                         
  with                                                                          
  our                                                                           
  Euro…                                                                         
  ORLA…                                                                         
  busi…                                                                         
  which                                                                         
  was                                                                           
  sold                                                                          
  to                                                                            
  Neop…                                                                         
  Gent…                                                                         
  S.p.…                                                                         
  on                                                                            
  Octo…                                                                         
  1,                                                                            
  2025:                                                                         
                                                                                
  ORLA…                                         $       38,6…                   
  reve…                                                                         
  Cost                                                                          
  of                                                                            
  prod…                                         $       2,465                   
  sales                                                                         
  -                                                                             
  ORLA…                                                                         
  Rese…                                                                         
  and                                                                           
  deve…                                         $       1,539                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Sales                                                                         
  and                                                                           
  mark…                                         $       30,4…                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Gene…                                                                         
  and                                                                           
  admi…                                         $       8,089                   
  (exc…                                                                         
  stoc…                                                                         
  comp…                                                                         
  Tran…                                         $       9,933                   
  costs                                                                         
  Stoc…                                         $       61,2…                   
  comp…                                                                         
  Loss                                                                          
  on                                                                            
  exti…                                         $       6,911                   
  of                                                                            
  debt                                                                          
  Reim…                                                                         
  of                                                                            
  tran…                                                                         
  costs                                                                         
  asso…                                                                         
  with                                                                          
  the                                                                           
  sale                                                                          
  of                                            $       (2,1…  )                
  our                                                                           
  Euro…                                                                         
  ORLA…                                                                         
  busi…                                                                         
  to                                                                            
  Neop…                                                                         
  Gent…                                                                         
  S.p.…                                                                         
  ²Cer…                                                                         
  tran…                                                                         
  costs                                                                         
  were                                                                          
  reim…                                                                         
  and                                                                           
  reco…                                                                         
  in                                                                            
  other                                                                         
  inco…                                                                         
                                                                                

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCRX/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.